Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years old) capable of providing informed consent. * For Hepatitis B+D groups: confirmed hepatitis B and D co-infection. * Bulevirtide group: receiving bulevirtide therapy as prescribed. * No Bulevirtide group: not receiving bulevirtide. * For Healthy Control group: systemically healthy adults without hepatitis B or D infection. * Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography. Exclusion Criteria: * Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases). * Patients currently receiving other experimental therapies that may affect oral or systemic inflammation. * Pregnancy or lactation. * Inability or unwillingness to provide informed consent. * History of oral or periodontal surgery within the last 6 months that could affect measurements.